Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.46 |
| ▸ | PPARD | Q03181 | 10/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586169 | 0.94 | PPARA (0.43) | PPARAPPARDPPARGHDAC1HDAC2 | |
| SCHEMBL13542095 | 0.87 | PPARD (0.41) | PPARAPPARDHDAC1HDAC2HDAC6 | |
| SCHEMBL3575263 | 0.85 | PPARA (0.47) | PPARAPPARDPPARGHDAC1HDAC2 | |
| SCHEMBL13542098 | 0.85 | PPARA (0.40) | PPARAPPARDPPARGHRH3 | |
| SCHEMBL3582668 | 0.83 | PPARA (0.43) | PPARAPPARDPPARGHRH3 | |
| SCHEMBL3584501 | 0.81 | PPARA (0.42) | PPARAPPARDPPARGHRH3ALDH1A1 | |
| SCHEMBL3578704 | 0.81 | PPARA (0.44) | PPARAPPARDPPARGHDAC1HDAC2 | |
| SCHEMBL13542092 | 0.81 | NAAA (0.42) | PPARAPPARDHDAC1HDAC2HDAC6 | |
| SCHEMBL14303751 | 0.81 | HDAC1 (0.42) | PPARAPPARDHDAC1HDAC2HDAC6 | |
| SCHEMBL3585140 | 0.79 | PPARA (0.47) | PPARAPPARDPPARGHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | PPARA 1138/4885PPARD 1213/4885PPARG 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.